Proposed bill would allow Pennsylvania students to take mental health days
Representative Napoleon Nelson (D-Montgomery County) called mental health a 'significant issue' among students and youth. Adding that in a 2023 report, 98,000 students have depression and over half had not received care for their mental health.
'Additionally, high school students with depression are more than two times more likely to drop out than their peers, and suicide is the second leading cause of death among adolescents,' Nelson wrote.
'Fanta's Law' aims to require Pennsylvania police firearms training courses
The proposed legislation would be modeled after a current law in Utah. The bill would allow students to take excused absences to recover from mental health issues, while not creating additional personal or sick days. An additional part of the legislation would require a staff member to talk to a student who has taken two or more mental health days.
In a memo to lawmakers, the additional part of the legislation would make it so that students can be connected to mental health support.
'Student mental health is just as important as physical health, and normalizing support for students with mental health issues has increased in the last several years. Teen mental health has been recognized as a crisis, and it is important for the Commonwealth to take charge in protecting the well-being of its citizens,' Nelson wrote.
Nelson argues that these are the benefits of the proposed legislation:
Normalizes mental health support and encourages students to take care of their mental health
Provides schools with additional insight
Would allow schools to connect students with essential supports rather than simply punishing them
The full memo to lawmakers can be read here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
7 hours ago
- Business Upturn
The Root Brands Achieves Major Milestone, ranked #1922 on Prestigious Inc. 5000 List of America's Fastest-Growing Private Companies
Franklin, TN, Aug. 13, 2025 (GLOBE NEWSWIRE) — The Root Brands, a breakthrough health and wellness company, achieved #1922 on the prestigious 2025 Inc. 5000 list of America's fastest-growing private companies. This elite recognition validates explosive revenue growth from $3 million to $61 million over four years, powered by patented nanotechnology detox solutions and innovative wellness products. 'This Inc. 5000 recognition validates our mission to revolutionize global health through natural detoxification and cutting-edge wellness solutions,' said Clayton Thomas, Founder and CEO. 'We're transforming lives worldwide by making premium health products accessible to everyone, everywhere.' Breakthrough Patented Technology Drives Market Disruption The Root Brands' meteoric rise stems from Dr. Christina Rahm's revolutionary patented formulations, including breakthrough water-soluble clinoptilolite technology for advanced detoxification. With 18 patent-pending innovations and 6 approved patents, Dr. Rahm's proprietary nanotechnology has created industry-leading wellness supplements that deliver measurable health results. The Trinity® Products – the company's flagship three-product system featuring Clean Slate®, Zero-In®, and Restore® – work synergistically to deliver comprehensive wellness results. This powerful trinity performs complete detoxification, mental clarity enhancement, and cellular restoration, creating the foundation for optimal health. This groundbreaking three-step approach has captured 220,000+ loyal customers across 90+ countries seeking effective holistic wellness solutions. 'Cure the Causes®' – Registered Healthcare Revolution Dr. Rahm's 'Cure the Causes®' philosophy, officially trademarked in July 2025, represents a paradigm shift from symptom treatment to root cause healing. This holistic healthcare approach has been translated into 27 languages, creating a global wellness movement that drives customer loyalty and organic growth. Power Partnership Fuels Success The dynamic partnership between CEO Clayton Thomas and his wife, Dr. Christina Rahm (Chief Science Officer), has pushed The Root Brands to unprecedented success. Their combined expertise in business strategy and scientific innovation creates a competitive advantage that competitors cannot replicate. Franklin Corporate Excellence The Root Brands' corporate headquarters in Franklin, Tennessee, drives continuous innovation across products, staff development, and global operations. This dedicated team ensures consistent delivery of premium wellness solutions to customers worldwide. Ambassador-Driven Marketing Success Unlike traditional advertising, The Root Brands achieves explosive growth through authentic customer testimonials and ambassador advocacy. Real success stories from satisfied customers create powerful word-of-mouth marketing that builds trust and drives organic expansion across global markets. The ROOT Prime subscription program ensures consistent product delivery while customer success stories fuel sustainable growth, creating a self-perpetuating business model that continues expanding internationally. About The Root Brands Founded in 2020 in Franklin, Tennessee, The Root Brands develops premium natural health supplements, detox products, and wellness solutions using patented nanotechnology. The company's 'Cure the Causes®' methodology focuses on root cause healing through advanced detoxification, serving customers in 90+ countries with organic, non-GMO, vegan, and gluten-free formulations. Core Products: The Trinity System (Clean Slate, Zero-In, Restore), Natural Barrier Support (immunity), Relive Greens (nutrition) Key Metrics: 220,000+ customers | 90+ countries | 20x growth since 2020 About Inc. 5000 The Inc. 5000 ranks America's fastest-growing private companies based on percentage revenue growth from 2021-2024, requiring minimum revenues of $100,000 (2021) and $2 million (2024). Past honorees include Microsoft, Facebook, Under Armor, and Chobani. Media Contact: Marty McGinley – VP MarketingThe Root BrandsPhone: (980) 400-3245 Email: [email protected] Address: 393 Nichol Mill Lane, Unit 250B, Franklin, TN 37067 Website:
Indianapolis Star
10 hours ago
- Indianapolis Star
Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates
Click here to register Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to register SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / August 12, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Thursday, August 14, 2025, at 8:30 a.m. Eastern to review second-quarter 2025 financials and provide corporate updates. Participation Instructions for Jaguar Investor Webcast When: Thursday, August 14, 2025 at 8:30 AM Eastern Time Participant Registration & Access Link: Click Here Participation Instructions for Jaguar's Virtual Presentation at the Emerging Growth Conference When: Wednesday, August 20, 2025 from 2:55 – 3:05 PM Eastern Time Where: Online (Click Here) Registration link for conference: Click Here Replay: An archived webcast of the presentation will be made available on and on the Emerging Growth YouTube Channel. About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi ® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Canalevia-CA1, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram Forward-Looking Statements Certain statements in this press release constitute 'forward-looking statements.' These include statements regarding the expectation that Jaguar will file its 10-Q on August 14, 2025 for the quarter ended June 30, 2025, the expectation that Jaguar will hold an investor webcast on August 14, 2025, and Jaguar's expectation that Jaguar management will present at the August 2025 Emerging Growth Conference. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: hello@ Jaguar-JAGX SOURCE: Jaguar Health, Inc.
Business Wire
11 hours ago
- Business Wire
Adagio Medical Reports Second Quarter 2025 Results
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ('Adagio' or 'the Company'), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2025. Recent Business Highlights: Surpassed 85% enrollment in the FULCRUM-VT pivotal study of the Company's vCLAS™ Cryoablation System. The study, which seeks to enroll 206 patients with either ischemic or non-ischemic drug-refractory, recurrent, sustained monomorphic ventricular tachycardia ('VT') at 20 U.S. and Canadian centers, is on track for completion of patient enrollment in the second half of 2025 First-in-human results from the PARALELL study, which evaluated the safety and effectiveness of Adagio's Pulsed Field Cryoablation ('PFCA'), a novel, dual-energy cardiac ablation modality combining Pulsed Field Ablation (PFA) with Adagio's proprietary Ultra-Low Temperature Cryoablation ('ULTC'), were published in the Journal of Cardiovascular Electrophysiology Reduced cash burn quarter-over-quarter as a result of the Company's corporate prioritization initiative, which streamlined operations and focused resources on highest-value programs 'In the second quarter we saw continued strong momentum in the enrollment of our FULCRUM-VT study, which we believe validates the market need for our purpose-built technology and brings us one step closer to offering our proprietary ULTC solutions to patients in the United States who suffer from ventricular tachycardia,' said Todd Usen, Chief Executive Officer of Adagio. 'The team also made meaningful progress in advancing our pipeline through the continued development of our next-generation product, which is designed to improve usability for physicians while further enhancing the capabilities of our differentiated ULTC platform.' Second Quarter 2025 Financial Results Cost of revenue was $0.3 million for the three months ended June 30, 2025, compared to $0.7 million for the three months ended June 30, 2024. Research and development expenses were $2.0 million for the three months ended June 30, 2025 compared to $2.9 million for the three months ended June 30, 2024 Selling, general and administrative expenses were $2.4 million for the three months ended June 30, 2025, compared to $3.4 million for the three months ended June 30, 2024. Net loss for the three months ended June 30, 2025, was $3.9 million, or $(0.26) per share (Basic), compared to a net loss of $5.7 million, or $(7.35) per share (Basic), for the three months ended June 30, 2024. Reported cash and cash equivalents of $8.2 million as of June 30, 2025. About Adagio Medical Holdings, Inc. Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Cryoablation (ULTC) technology. ULTC is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The Company is currently focused on the treatment of ventricular tachycardia (VT) with its purpose-built vCLAS™ Cryoablation System, which is CE Marked and is currently under evaluation in the Company's FULCRUM-VT U.S. IDE Pivotal Study. About FULCRUM VT FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia) is a prospective, multi-center, open-label, single-arm study, enrolling 206 patients with structural heart disease of both ischemic and non-ischemic cardiomyopathy, indicated for catheter ablation of drug refractory VT in accordance with current treatment guidelines. The results of the study will be used to apply for FDA premarket approval (PMA) for Adagio's vCLAS™ Cryoablation System, potentially leading to the broadest industry indication for purely endocardial ablation of scar-mediated VT. Adagio's vCLAS™ Cryoablation System is commercially available for the treatment of monomorphic ventricular tachycardia in Europe and select other geographies but is limited to investigational use in the United States. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'projects,' 'plans,' and 'future' or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning: the potential of Adagio's vCLAS™ Cryoablation System; Adagio's research, development and regulatory plans for its product candidates, including the timing of initiating additional trials and reporting data from its trials; the ability of Adagio to bring its proprietary ULTC solutions to patients in the United States who suffer from VT and their ability to improve usability for physicians; the potential for its product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies; and its current cash resources and the impacts of its corporate prioritization initiative and realignment of resources. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Adagio's business are described in detail in Adagio's Securities and Exchange Commission ('SEC') filings, including in its Annual Report on Form 10-K for the full-year ended December 31, 2024, which is available on the SEC's website at Additional information will be made available in other filings that Adagio makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Adagio disclaims any obligation to update these statements except as may be required by law.
